Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | WDR5 | P61964 | 3/20 | 0.38 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | FASN | P49327 | 2/20 | 0.38 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929345 | 0.99 | HTR1A (0.38) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL928437 | 0.98 | CYP2C9 (0.38) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL929105 | 0.95 | CYP2C9 (0.39) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL929745 | 0.94 | CYP2C9 (0.39) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL929273 | 0.94 | CYP2C9 (0.37) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL10207836 | 0.91 | CYP2C9 (0.36) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL10207841 | 0.91 | CYP2C9 (0.39) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL10207828 | 0.91 | CYP2C9 (0.39) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL10207843 | 0.91 | CYP2C9 (0.39) | CYP2C9HTR1AKMT2ALMNAWDR5 | |
| SCHEMBL714213 | 0.91 | CYP2C9 (0.35) | CYP2C9HTR1AKMT2ALMNAWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | claimed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | claimed |
| EP-2065379-A1 | BENZIMIDAZOLE COMPOUND HAVING GASTRIC ACID SECRETION INHIBITORY ACTIVITY | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | claimed |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-2065379-A1 | BENZIMIDAZOLE COMPOUND HAVING GASTRIC ACID SECRETION INHIBITORY ACTIVITY | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
| EP-2065379-A1 | BENZIMIDAZOLE COMPOUND HAVING GASTRIC ACID SECRETION INHIBITORY ACTIVITY | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | CYP2C9 255/4885HTR1A 791/4885KMT2A 4196/4885 |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | CYP2C9 255/4885HTR1A 791/4885KMT2A 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.